Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast and gemfibrozil added to CyBorD for progressive multiple myeloma
ACTRN12617001516370Phase 3Active, not recruiting
- Sponsor
- Dr Stephen Kenneth O'Mara
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of montelukast, gemfibrozil, bortezomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by Dr Stephen Kenneth O'Mara. Primary endpoints: Change in serum M protein or serum light chain and Unexpected side effects. Started Sep 2016; status: active, not recruiting.
02
Drugs
montelukastgemfibrozilbortezomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12617001516370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001516370.